Another page is written these days in the scandal around
pharmaceutical companies paying good...
|
According to The New York Times, the benefits and risks a cholesterol-lowering drug poses are still...
|
Vytorin is a “best-selling” and heavily promoted cholesterol
lowering drug. It is a composite of...
|
Vytorin prescriptions drop as studies link the cholesterol drug with higher numbers of cancer...
|
The debate over Vytorin’s cancer risk
continues as results of a controversial Vytorin study,...
|
The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial found out that the drug Vytorin, used...
|
Earlier this year, it was revealed that the U.S. spent $1.5 billion in 2006 on Vytorin, a...
|
A recent study on cholesterol-lowering drug Vytorin, called
SEAS, linking it to an increased risk...
|
Even though a study conducted last year announced that there
might be connection between...
|
A report appeared in the August 19 issue of the Annals of
Internal Medicine reveals that a 1999...
|
The American Academy of Pediatrics has changed its guidelines, recommending testing of overweight...
|
A key cardiologist who worked with Merck and Schering-Plough on a comprehensive study on their...
|
Top U.S.
heart doctors warned Sunday at the American
College of Cardiology’s annual meeting
in...
|
U.S. researchers announced Friday they would expand the size of a major study involving...
|
The decision on Vytorin has yet
to be taken, as health officials continue discussions on the...
|
